Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients

LAUR Repository

Show simple item record

dc.contributor.author Nasser, Soumana C.
dc.contributor.author Dimassi, Hani I.
dc.contributor.author Nassif, Jeanette G.
dc.date.accessioned 2015-10-01T10:20:29Z
dc.date.available 2015-10-01T10:20:29Z
dc.date.copyright 2010-02-28
dc.date.issued 2015-10-01
dc.identifier.issn 1007-9327 en_US
dc.identifier.uri http://hdl.handle.net/10725/2230
dc.description.abstract AIM: To assess the appropriateness of the indication and route of administration of proton-pump-inhibitors (PPIs) and their associated cost impact. METHODS: Data collection was performed prospectively during a 6-mo period on 340 patients who received omeprazole intravenously during their hospital stay in non-intensive care floors. Updated guidelines were used to assess the appropriateness of the indication and route of administration. RESULTS: Complete data collection was available for 286 patients which were used to assess intravenous (IV) PPIs utilization. Around 88% of patients were receiving PPIs for claimed stress ulcer prophylaxis (SUP) indication; of which, only 17% met the guideline criteria for SUP indication, 14% met the criteria for non-steroidal-anti-inflammatory drugs-induced ulcer prophylaxis, while the remaining 69% were identified as having an unjustified indication for PPI use. The initiation of IV PPIs was appropriate in 55% of patients. Half of these patients were candidates for switching to the oral dosage form during their hospitalization, while only 36.7% of these patients were actually switched. The inappropriate initiation of PPIs via the IV route was more likely to take place on the medical floor than the surgical floor (53% vs 36%, P = 0.003). The cost analysis associated with the appropriateness of the indication for PPI use as well as the route of administration of PPI revealed a possible saving of up to $17 732.5 and $14 571, respectively. CONCLUSION: This study highlights the over-utilization of IV PPIs in non-intensive care unit patients. Restriction of IV PPI use for justified indications and route of administration is recommended. en_US
dc.language.iso en en_US
dc.title Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOP en_US
dc.author.idnumber 199231640 en_US
dc.author.idnumber 200603781
dc.author.woa N/A en_US
dc.author.department Pharmacy en_US
dc.description.embargo N/A en_US
dc.relation.journal World Journal of Gastroenterology en_US
dc.journal.volume 16 en_US
dc.journal.issue 8 en_US
dc.article.pages 982-986 en_US
dc.keywords Cost saving en_US
dc.keywords Lebanon en_US
dc.keywords Non-intensive care unit patients en_US
dc.keywords Omeprazole en_US
dc.keywords Over-utilization en_US
dc.keywords Proton-pump-inhibitors en_US
dc.keywords Stress ulcer prophylaxis en_US
dc.identifier.doi http://dx.doi.org/10.3748/wjg.v16.i8.982 en_US
dc.identifier.ctation Nasser, S. C., Nassif, J. G., & Dimassi, H. I. (2010). Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients. World journal of gastroenterology: WJG, 16(8), 982. en_US
dc.author.email soumana.nasser@lau.edu.lb
dc.author.email hani.dimassi@lau.edu.lb
dc.identifier.url http://www.wjgnet.com/1007-9327/full/v16/i8/982.htm

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account